# Femasys Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Femasys Inc). ## Overview Femasys Inc. is a U.S.-based medical technology company developing and commercializing women’s health products, with current focus on FemaSeed and its investigational product FemBloc. The company is still in a development-and-commercialization phase, funding clinical, regulatory, manufacturing, and sales efforts while it works to expand adoption and obtain approval for its pipeline. ## Products & services • FemaSeed fertility treatment product • FemBloc permanent birth control candidate • Clinical development and pivotal trial services • Regulatory, manufacturing and commercialization activities • Sales and marketing for women’s health products - **Commercial women’s health products** (35%) — Currently marketed products and related commercialization efforts, including FemaSeed. - **Pipeline product development** (45%) — Clinical and regulatory development of FemBloc and future product candidates. - **Manufacturing and supply chain** (10%) — Production, sourcing, and supply support needed to make and ship products. - **Sales and marketing** (10%) — Commercial organization and market-building activities for current and future products. - FemaSeed fertility treatment product - FemBloc permanent birth control candidate - Clinical development and pivotal trial services - Regulatory, manufacturing and commercialization activities - Sales and marketing for women’s health products ## Customers The company sells to healthcare customers and distributors that buy women’s health products for clinical use and resale. Its commercial model also depends on physicians, clinics, and other providers that influence adoption of FemaSeed, while FemBloc’s future customer base depends on regulatory approval and market access. International distributors are specifically mentioned as part of the shipping and sales model. - **U.S. healthcare customers** (primary) — Buy current products shipped directly in the U.S.; they value availability, clinical utility, and reliable fulfillment. - **International distributors** (secondary) — Purchase products for resale under EX-Works terms and extend the company’s reach outside the U.S. - **Physicians and clinics** (primary) — Influence adoption of FemaSeed and potential FemBloc use by choosing products for patient care. - **Future FemBloc market** (emerging) — Represents the addressable customer base if FemBloc clears regulatory review and commercialization. - Physicians and clinics using women’s health products in practice - Healthcare distributors reselling products in international markets - U.S. customers buying shipped goods on FOB shipping point terms - Future FemBloc users if the product receives regulatory approval - Providers seeking fertility or contraception-related solutions ## Geography Femasys is headquartered in the United States and appears operationally centered there, with direct U.S. shipping and commercialization as the core business. The company also serves international distributors, so non-U.S. markets matter for future expansion, but the filings provided do not disclose a country revenue split. Geography is important because U.S. regulatory approval, FDA timing, and domestic commercialization are central to the company’s near-term execution. - Headquartered and primarily operated in the United States - Direct U.S. shipments are a core part of current sales - International distributors support non-U.S. market access - FDA review is critical for U.S. product candidate FemBloc - No country revenue split was disclosed in the excerpts ## Strategy The company’s near-term strategy is to fund and complete the pivotal trial for FemBloc while continuing commercialization of FemaSeed. It also needs to build sales, marketing, manufacturing, and regulatory capabilities, which makes capital raising a central strategic priority. Longer term, success depends on converting clinical evidence into approval, market access, and broader product expansion. - **Complete FemBloc pivotal trial** (short-term) — Clinical evidence is required to support approval and future commercialization. - **Secure additional financing** (short-term) — Cash on hand is not sufficient to sustain operations and development plans. - **Scale commercialization of FemaSeed** (medium-term) — Current product sales help establish the platform and support future adoption. - Advance the FemBloc pivotal trial toward regulatory approval - Commercialize FemaSeed while building market awareness - Expand sales, marketing, and distribution capabilities - Invest in manufacturing and supply continuity - Raise additional capital to fund operations and development ## Risks Femasys faces substantial going-concern and financing risk because management states cash is insufficient to sustain operations without additional capital. The company is also exposed to clinical, regulatory, and commercialization risk: delays or setbacks in the FemBloc trial or FDA review could materially slow or prevent product launch, while Nasdaq listing compliance adds market and financing pressure. As a medical device company, it also faces execution risk around manufacturing, supply continuity, and adoption by providers and distributors. - **Liquidity and going-concern risk** [critical] — Management says current cash is not sufficient to fund operations and development. - **Clinical and regulatory approval risk** [high] — FemBloc depends on successful pivotal trial results and FDA review. - **Nasdaq delisting risk** [high] — The company received deficiency notices tied to continued listing requirements. - **Commercialization and adoption risk** [medium] — Revenue depends on physician, clinic, and distributor uptake of products. - Insufficient cash may force delays, dilution, or cessation of operations - FemBloc trial or FDA delays could postpone approval and commercialization - Nasdaq listing non-compliance could lead to delisting risk - Commercial adoption risk if physicians and distributors do not scale usage - Manufacturing and supply disruptions could limit product availability ## Accounting Revenue is recognized at a point in time when control transfers, generally upon shipment, which makes shipment timing important for quarterly comparability. The company also has judgment-heavy estimates around operating losses, financing-related items, and stock-based compensation, all of which can materially affect reported results in a development-stage business. Returns appear limited, but the 30% restocking fee and shipping terms matter for gross revenue presentation and cut-off. - **Point-in-time revenue recognition** — Quarterly revenue comparability - **Shipping terms and transfer of control** — Revenue cut-off and returns handling - **Stock-based compensation and convertible note amortization** — Net loss and operating expense presentation - **Going-concern and financing assumptions** — Financial statement estimates and disclosure risk - Revenue is recognized on shipment, so quarter-end cut-off matters - U.S. FOB shipping point and EX-Works terms affect transfer of control - Sales taxes are excluded from transaction price under Topic 606 - Stock-based compensation and note discount amortization affect losses - Going-concern and financing assumptions may affect estimates --- *Last updated: 2026-04-28T20:06:19.763373+00:00*